G protein-coupled receptor kinases phosphorylate activated G protein-coupled receptors, which promotes the binding of an arrestin protein to the receptor. Arrestin binding to phosphorylated, active receptor prevents receptor stimulation of heterotrimeric G protein transducer proteins, blocking their cellular signaling and resulting in receptor desensitization. Arrestin binding also directs receptors to specific cellular internalization pathways, removing the receptors from the cell surface and also preventing additional activation. Arrestin binding to phosphorylated, active receptor also enables receptor signaling through arrestin partner proteins. Thus the GRK/arrestin system serves as a complex signaling switch for G protein-coupled receptors.
GRK3 and the closely-related GRK2 phosphorylate receptors at sites that encourage arrestin-mediated receptor desensitization, internalization and trafficking rather than arrestin-mediated signaling (in contrast to GRK5 and GRK6, which have the opposite effect). This difference is one basis for pharmacological biased agonism (also called functional selectivity), where a drug binding to a receptor may bias that receptor’s signaling toward a particular subset of the actions stimulated by that receptor. 
GRK3 is expressed broadly in tissues, but generally at lower levels than the related GRK2. GRK3 has particularly high expression in olfactory neurons, and mice lacking the ADRBK2 gene exhibit defects in olfaction.Gene linkage techniques were used to identify a polymorphism in the promoter of the human ADRBK2 gene as a possible cause of up to 10% of cases of bipolar disorder. However, the significance of GRK3 in bipolar disorder has been controversial due to conflicting reports. GRK3 has also been implicated in regulation of dopamine receptors in Parkinson’s disease in animal models. Reduced expression of GRK3 has been associated with the immunodeficientWHIM syndrome in humans, and appears causative in a mouse model of the disease.
^Calabrese G, Sallese M, Stornaiuolo A, Stuppia L, Palka G, De Blasi A (September 1994). "Chromosome mapping of the human arrestin (SAG), beta-arrestin 2 (ARRB2), and beta-adrenergic receptor kinase 2 (ADRBK2) genes". Genomics. 23 (1): 286–8. doi:10.1006/geno.1994.1497. PMID7695743.
^Benovic JL, Onorato JJ, Arriza JL, Stone WC, Lohse M, Jenkins NA, Gilbert DJ, Copeland NG, Caron MG, Lefkowitz RJ (August 1991). "Cloning, expression, and chromosomal localization of beta-adrenergic receptor kinase 2. A new member of the receptor kinase family". The Journal of Biological Chemistry. 266 (23): 14939–46. PMID1869533.
^Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, Lefkowitz RJ (February 2005). "Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling". Proceedings of the National Academy of Sciences of the United States of America. 102 (5): 1442–7. doi:10.1073/pnas.0409532102. PMID15671181.
^Ren XR, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ (February 2005). "Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor". Proceedings of the National Academy of Sciences of the United States of America. 102 (5): 1448–53. doi:10.1073/pnas.0409534102. PMID15671180.
^Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ (June 2009). "Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands". Proceedings of the National Academy of Sciences of the United States of America. 106 (24): 9649–54. doi:10.1073/pnas.0904361106. PMID19497875.
^Arriza JL, Dawson TM, Simerly RB, Martin LJ, Caron MG, Snyder SH, Lefkowitz RJ (October 1992). "The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain". The Journal of Neuroscience. 12 (10): 4045–55. PMID1403099.
^Boekhoff I, Inglese J, Schleicher S, Koch WJ, Lefkowitz RJ, Breer H (January 1994). "Olfactory desensitization requires membrane targeting of receptor kinase mediated by beta gamma-subunits of heterotrimeric G proteins". The Journal of Biological Chemistry. 269 (1): 37–40. PMID8276821.
^Barrett TB, Hauger RL, Kennedy JL, Sadovnick AD, Remick RA, Keck PE, McElroy SL, Alexander M, Shaw SH, Kelsoe JR (May 2003). "Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder". Molecular Psychiatry. 8 (5): 546–57. doi:10.1038/sj.mp.4001268. PMID12808434.
^Luykx JJ, Boks MP, Terwindt AP, Bakker S, Kahn RS, Ophoff RA (June 2010). "The involvement of GSK3beta in bipolar disorder: integrating evidence from multiple types of genetic studies". European Neuropsychopharmacology. 20 (6): 357–68. doi:10.1016/j.euroneuro.2010.02.008. PMID20226637.
^Ahmed MR, Bychkov E, Li L, Gurevich VV, Gurevich EV (June 2015). "GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain". Scientific Reports. 5: 10920. doi:10.1038/srep10920. PMID26043205.
Benovic JL, Onorato JJ, Arriza JL, Stone WC, Lohse M, Jenkins NA, Gilbert DJ, Copeland NG, Caron MG, Lefkowitz RJ (August 1991). "Cloning, expression, and chromosomal localization of beta-adrenergic receptor kinase 2. A new member of the receptor kinase family". The Journal of Biological Chemistry. 266 (23): 14939–46. PMID1869533.
Parruti G, Ambrosini G, Sallese M, De Blasi A (January 1993). "Molecular cloning, functional expression and mRNA analysis of human beta-adrenergic receptor kinase 2". Biochemical and Biophysical Research Communications. 190 (2): 475–81. doi:10.1006/bbrc.1993.1072. PMID8427589.
Oppermann M, Freedman NJ, Alexander RW, Lefkowitz RJ (May 1996). "Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C". The Journal of Biological Chemistry. 271 (22): 13266–72. doi:10.1074/jbc.271.22.13266. PMID8662816.
Oppermann M, Mack M, Proudfoot AE, Olbrich H (March 1999). "Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus". The Journal of Biological Chemistry. 274 (13): 8875–85. doi:10.1074/jbc.274.13.8875. PMID10085131.
Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP (December 1999). "The DNA sequence of human chromosome 22". Nature. 402 (6761): 489–95. doi:10.1038/990031. PMID10591208.
Inngjerdingen M, Damaj B, Maghazachi AA (April 2000). "Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309". Journal of Immunology. 164 (8): 4048–54. doi:10.4049/jimmunol.164.8.4048. PMID10754297.
Celver JP, Lowe J, Kovoor A, Gurevich VV, Chavkin C (February 2001). "Threonine 180 is required for G-protein-coupled receptor kinase 3- and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in Xenopus oocytes". The Journal of Biological Chemistry. 276 (7): 4894–900. doi:10.1074/jbc.M007437200. PMID11060299.
Blaukat A, Pizard A, Breit A, Wernstedt C, Alhenc-Gelas F, Muller-Esterl W, Dikic I (November 2001). "Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function". The Journal of Biological Chemistry. 276 (44): 40431–40. doi:10.1074/jbc.M107024200. PMID11517230.
Wang J, Guan E, Roderiquez G, Calvert V, Alvarez R, Norcross MA (December 2001). "Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages". The Journal of Biological Chemistry. 276 (52): 49236–43. doi:10.1074/jbc.M108523200. PMID11668182.
Obara K, Arai K, Tomita Y, Hatano A, Takahashi K (October 2001). "G-protein coupled receptor kinase 2 and 3 expression in human detrusor cultured smooth muscle cells". Urological Research. 29 (5): 325–9. doi:10.1007/s002400100207. PMID11762794.
Mandyam CD, Thakker DR, Christensen JL, Standifer KM (August 2002). "Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk". The Journal of Pharmacology and Experimental Therapeutics. 302 (2): 502–9. doi:10.1124/jpet.102.033159. PMID12130708.
Barrett TB, Hauger RL, Kennedy JL, Sadovnick AD, Remick RA, Keck PE, McElroy SL, Alexander M, Shaw SH, Kelsoe JR (May 2003). "Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder". Molecular Psychiatry. 8 (5): 546–57. doi:10.1038/sj.mp.4001268. PMID12808434.
Dzimiri N, Muiya P, Andres E, Al-Halees Z (April 2004). "Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases". European Journal of Pharmacology. 489 (3): 167–77. doi:10.1016/j.ejphar.2004.03.015. PMID15087239.
Teli T, Markovic D, Levine MA, Hillhouse EW, Grammatopoulos DK (February 2005). "Regulation of corticotropin-releasing hormone receptor type 1alpha signaling: structural determinants for G protein-coupled receptor kinase-mediated phosphorylation and agonist-mediated desensitization". Molecular Endocrinology. 19 (2): 474–90. doi:10.1210/me.2004-0275. PMID15498832.